Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reviving immunogenic cell death upon targeting TACC3 enhances T-DM1 response in HER2-positive breast cancer.
Gedik ME, Saatci O, Oberholtzer N, Uner M, Akbulut O, Cetin M, Aras M, Ibis K, Caliskan B, Banoglu E, Wiemann S, Uner A, Aksoy S, Mehrotra S, Sahin O. Gedik ME, et al. Among authors: saatci o. bioRxiv [Preprint]. 2023 Sep 14:2023.09.12.557273. doi: 10.1101/2023.09.12.557273. bioRxiv. 2023. Update in: Cancer Res. 2024 May 2;84(9):1475-1490. doi: 10.1158/0008-5472.CAN-23-2812 PMID: 37745348 Free PMC article. Updated. Preprint.
The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer.
Raza U, Saatci Ö, Uhlmann S, Ansari SA, Eyüpoğlu E, Yurdusev E, Mutlu M, Ersan PG, Altundağ MK, Zhang JD, Doğan HT, Güler G, Şahin Ö. Raza U, et al. Among authors: saatci o. Oncotarget. 2016 Aug 2;7(31):49859-49877. doi: 10.18632/oncotarget.10489. Oncotarget. 2016. PMID: 27409664 Free PMC article.
Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer.
Mishra RR, Belder N, Ansari SA, Kayhan M, Bal H, Raza U, Ersan PG, Tokat ÜM, Eyüpoğlu E, Saatci Ö, Jandaghi P, Wiemann S, Üner A, Cekic C, Riazalhosseini Y, Şahin Ö. Mishra RR, et al. Among authors: saatci o. Clin Cancer Res. 2018 Apr 15;24(8):1987-2001. doi: 10.1158/1078-0432.CCR-17-2776. Epub 2018 Jan 31. Clin Cancer Res. 2018. PMID: 29386221
Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers.
Siddiqui A, Gollavilli PN, Schwab A, Vazakidou ME, Ersan PG, Ramakrishnan M, Pluim D, Coggins S, Saatci O, Annaratone L, Hm Schellens J, Kim B, Asangani IA, Rasheed SAK, Marchiò C, Sahin O, Ceppi P. Siddiqui A, et al. Among authors: saatci o. Cell Death Differ. 2019 Nov;26(11):2223-2236. doi: 10.1038/s41418-019-0289-6. Epub 2019 Feb 8. Cell Death Differ. 2019. PMID: 30737477 Free PMC article.
Systems-level Analysis Reveals Multiple Modulators of Epithelial-mesenchymal Transition and Identifies DNAJB4 and CD81 as Novel Metastasis Inducers in Breast Cancer.
Uretmen Kagiali ZC, Sanal E, Karayel Ö, Polat AN, Saatci Ö, Ersan PG, Trappe K, Renard BY, Önder TT, Tuncbag N, Şahin Ö, Ozlu N. Uretmen Kagiali ZC, et al. Among authors: saatci o. Mol Cell Proteomics. 2019 Sep;18(9):1756-1771. doi: 10.1074/mcp.RA119.001446. Epub 2019 Jun 20. Mol Cell Proteomics. 2019. PMID: 31221721 Free PMC article.
A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate.
Akbulut O, Lengerli D, Saatci O, Duman E, Seker UOS, Isik A, Akyol A, Caliskan B, Banoglu E, Sahin O. Akbulut O, et al. Among authors: saatci o. Mol Cancer Ther. 2020 Jun;19(6):1243-1254. doi: 10.1158/1535-7163.MCT-19-0957. Epub 2020 Mar 26. Mol Cancer Ther. 2020. PMID: 32217742
80 results